NCT04678947终止不适用
The BARF Project: A Pilot Study Using the BARF Scale to Assess CINV in Children
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- Doses of anti-emetic medication administered during inpatient chemotherapy admissions
研究概览
简要总结
In this pilot study, the Baxter Retching Faces (BARF) Scale will be used to assess chemotherapy induced nausea and vomiting (CINV) in the pediatric cancer population during chemotherapy admissions, and the corresponding administration of anti-emetic medications will be reviewed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Health Services Research
- 盲法
- None
入排标准
- 年龄范围
- 4 Years 至 12 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients diagnosed with cancer of any kind.
- •Patients receiving inpatient chemotherapy at SLCH on the general pediatric oncology service
- •Patients admitted for a course of inpatient chemotherapy scheduled to last at least 24 hours and but no more than 7 days.
- •Patients who have received any prior cancer treatment, including radiation therapy, and/or surgery.
- •Patients ages 4 to 12 years of age.
- •Patient with a guardian who has the ability to understand English and the willingness to sign an IRB approved written informed consent document.
排除标准
- •Any patient who is not undergoing inpatient chemotherapy on the general pediatric oncology service, including patients undergoing chemotherapy as conditioning for hematopoietic stem cell transplantation or other cellular therapy.
- •Any patient who is receiving their first cycle of inpatient chemotherapy (however, they can be included during a future cycle).
- •Any patient who is blind or unable to communicate by speaking or pointing.
研究组 & 干预措施
BARF scale
Experimental
- Nursing staff (which may include patient technicians and nursing assistants) will use the scale to assess the patient's nausea for the entire duration of the admission. These assessments will take place in conjunction with vital sign monitoring, every 4 hours. The associated script will be read while the laminated scale is shown to the patient.
- The nurse will then log the patient's response in the patient's electronic medical record
干预措施: Baxter Retching Faces (BARF) scale (Behavioral)
No intervention
No Intervention
-Patients in the control group will proceed with their inpatient chemotherapy admissions without any interventions. These admissions will take place prior to the admissions of the experimental group, so as not to bias providers.
结局指标
主要结局
Doses of anti-emetic medication administered during inpatient chemotherapy admissions
时间窗: 24 hours - 7 days (estimated)
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple MyelomaMultiple MyelomaNCT05346198Shanghai Simnova Biotechnology Co.,Ltd.15
已完成
2 期
Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast CancerBreast NeoplasmsNCT00110695NSABP Foundation Inc66
进行中（未招募）
1 期
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic CancerPancreatic CancerNCT05984602NYU Langone Health9
暂停
1 期
Using Aspirin to Improve Immunological Features of Ovarian TumorsFallopian Tube CancerPeritoneal CancerOvarian CancerNCT05080946H. Lee Moffitt Cancer Center and Research Institute100
招募中
1 期
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic MalignanciesRecurrent Chronic Lymphocytic LeukemiaRecurrent Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Transformed Chronic Lymphocytic LeukemiaRefractory Mantle Cell LymphomaRefractory Transformed Chronic Lymphocytic LeukemiaB-Cell Non-Hodgkin LymphomaRecurrent Small Lymphocytic LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Follicular LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Marginal Zone LymphomaRefractory Small Lymphocytic LymphomaRecurrent Diffuse Large B-Cell LymphomaNCT06191887Mayo Clinic27